Evidence map›Paper›PMID 35042948›Full record

Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2022

EEG reveals that dextroamphetamine improves cognitive control through multiple processes in healthy participants.

Savita G Bhakta, James F Cavanagh, Jo A Talledo, Juliana E Kotz, Lindsay Benster, Benjamin Z Roberts, John A Nungaray, Jonathan L Brigman, Gregory A Light, Neal R Swerdlow and 1 more

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Cigarette smoking is associated with reduced neuroinflammation and better cognitive control in people living with HIV.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Savita G BhaktaDepartment of Psychiatry, University of California, 9500 Gilman Drive, La Jolla, San Diego, CA, 92093, USA.
James F CavanaghPsychology Department, University of New Mexico, Albuquerque, NM, USA.
Jo A TalledoDepartment of Psychiatry, University of California, 9500 Gilman Drive, La Jolla, San Diego, CA, 92093, USA.
Juliana E KotzDepartment of Psychiatry, University of California, 9500 Gilman Drive, La Jolla, San Diego, CA, 92093, USA.
Lindsay BensterDepartment of Psychiatry, University of California, 9500 Gilman Drive, La Jolla, San Diego, CA, 92093, USA.
Benjamin Z RobertsDepartment of Psychiatry, University of California, 9500 Gilman Drive, La Jolla, San Diego, CA, 92093, USA.
John A NungarayDepartment of Psychiatry, University of California, 9500 Gilman Drive, La Jolla, San Diego, CA, 92093, USA.
Jonathan L BrigmanDepartment of Neurosciences, University of New Mexico School of Medicine, Albuquerque, NM, 87131, USA.
Gregory A LightDepartment of Psychiatry, University of California, 9500 Gilman Drive, La Jolla, San Diego, CA, 92093, USA.
Neal R SwerdlowDepartment of Psychiatry, University of California, 9500 Gilman Drive, La Jolla, San Diego, CA, 92093, USA.
Jared W YoungDepartment of Psychiatry, University of California, 9500 Gilman Drive, La Jolla, San Diego, CA, 92093, USA. jaredyoung@ucsd.edu.ORCID http://orcid.org/0000-0003-3732-5776
University of California San Diego · USUniversity of New Mexico · US

Funding

Neurosciences Graduate Training ProgramT32NS061847 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Brenda L Bloodgood · 2008 to 2026
$7.7M
Cannabis use and the endocannabinoid system in bipolar disorderR01DA043535 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI PERRY, WILLIAM, YOUNG, JARED WILLIAM · 2018 to 2022
$3.3M
Neurophysiological biomarkers of behavioral dimensions from cross-species paradigmsUH3MH109168 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI YOUNG, JARED WILLIAM · 2018 to 2019
$1.0M
NIDA NIH HHS R01 DA043535NIMH NIH HHS UH3 MH109168NINDS NIH HHS T32 NS061847
6 · The paper itself

Abstract

The poor translatability between preclinical and clinical drug trials has limited pro-cognitive therapeutic development. Future pro-cognitive drug trials should use translatable cross-species cognitive tasks with biomarkers (1) relevant to specific cognitive constructs, and (2) sensitive to drug treatment. Here, we used a difficulty-modulated variant of a cross-species cognitive control task with simultaneous electroencephalography (EEG) to identify neurophysiological biomarkers sensitive to the pro-cognitive effects of dextroamphetamine (d-amp) (10 or 20 mg) in healthy adults (n = 23), in a randomized, placebo-controlled, counterbalanced, double blind, within-subject study, conducted across three test days each separated by one week. D-amp boosted d-prime, sped reaction time, and increased frontal P3a amplitude to non-target correct rejections independent of task difficulty. Task difficulty did however, moderate d-amp effects on EEG during target performance. D-amp suppressed frontal theta power during easy target responses which negatively correlated with drug-induced improvement in hit rate while d-amp-induced changes in P3b amplitude during hard target trials strongly correlated with drug-induced improvement in hit rate. In summary, d-amp affected both behavioral and neurophysiological measures of cognitive control elements. Under low-demand, d-amp diminished cognitive control by suppressing theta, yet under high-demand it boosted control in concert with higher P3b amplitudes. These findings thus appear to reflect a gain-sharpening effect of d-amp: during high-demand processes were boosted while during low-demand processes were neglected. Future studies will use these neurophysiological measures of cognitive control as biomarkers to predict d-amp sensitivity in people with cognitive control deficits, including schizophrenia.

Indexed as

CognitionElectroencephalographyAdultDextroamphetamineHealthy VolunteersHumansDextroamphetamine

Identifiers

PMID35042948
PMCPMC8938448
OpenAlexW4206234073

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.